Instruction for use: ProveraI want this, give me price
Active substance Medroxyprogesterone
ATX code G03DA02 Medroxyprogesterone
Estrogens, gestagens; Their homologues and antagonists
Antineoplastic hormonal agents and hormone antagonists
Nosological classification (ICD-10)
C50 Malignant neoplasm of breast
Cancer of the nipple and areola of the breast, Breast carcinoma, The hormone-dependent form of recurrent breast cancer in women in menopause, Hormone-dependent breast cancer, Disseminated breast carcinoma, Disseminated Breast Cancer, Malignant breast cancer, Malignant neoplasm of breast, Contralateral breast cancer, Locally advanced or metastatic breast cancer,Locally-distributed breast cancer, Locally-recurring breast cancer, Metastatic breast carcinoma, Metastasis of breast tumors, Metastatic breast carcinoma, Inoperable breast carcinoma, Incompatible breast cancer, Breast cancer in women with metastases, Breast cancer in men with metastases, Breast Cancer, Breast cancer in men, Mammary cancer, Breast cancer with distant metastases, Breast cancer in postmenopausal women, Breast cancer hormone-dependent, Breast cancer with local metastases, Breast cancer with metastases, Breast cancer with regional metastases,Breast cancer with metastases, Common hormone-dependent forms of breast cancer, Common Breast Cancer, Recurrent Breast Cancer, Recurrence of breast tumors, Breast cancer, Estrogen-dependent breast cancer, Estrogen-Dependent Breast Cancer, Disseminated breast cancer with overexpression of HER2, Tumors of the mammary glands
C54.1 Malignant neoplasm of endometrium
Recurrent inoperable endometrial cancer, Endometrial cancer, Metastatic endometrial carcinoma, Metastatic Endometrial Cancer, Endometrial carcinoma, Recurrent carcinomas of the endometrium, Recurrent endometrial cancer
C64 Malignant neoplasm of kidney, except for renal pelvis
Wilms swelling, Kidney Cancer, Metastatic Renal Cell Carcinoma, Renal carcinoma, Inoperable kidney carcinomas, Metastatic kidney carcinoma, Metastatic Renal Cell Carcinoma, Wilms tumor, Wilms swelling, Adenomyosarcoma, Adenomyocystosarcoma, Adenosarcoma of the kidney, Kidney Cancer, Common renal cell carcinoma, Nephroblastoma, Nephroma, Embryonal nephroma, Recurrent carcinoma of the kidney, Birch-Hirschfeld Tumor, Common renal cell carcinoma, Tumors of the kidney
Composition and form of release
Tablets 1 table.
Medroxyprogesterone acetate 100 mg \ 500 mg
Auxiliary substances: corn starch; Magnesium stearate; MCC; gelatin; Polyethylene glycol 400; Sodium starch; Docusate sodium (85%) with sodium benzoate (15%)
In a planar cell pack of 10; In a pack of cardboard 3 packs.
Description of dosage form
Tablets of 100 mg: white, round, flat with a notch.
Tablets of 500 mg: white, oblong, biconvex.
Pharmacological action - antitumor, progestogen.
Hormone-dependent forms of recurrent breast cancer in women in menopause (palliative care), recurrent and / or metastatic endometrial cancer, kidney (additional and / or palliative treatment).
From the nervous system and sensory organs: dizziness, headache, nervousness, sleep disorders, drowsiness, weakness, depression.
From the cardiovascular system and blood (hematopoiesis, hemostasis): thromboembolism, thrombophlebitis.
Allergic reactions: rashes, hives; In some cases - anaphylactoid reactions.
Other: nausea, tenderness of the mammary glands, galactorrhea, fever, symptomatic complex Itenko-Cushing (with prolonged intake of high doses).
Dosing and Administration
Inside, with recurrent breast cancer in women in menopause at 400-1200 mg / day, with recurrent endometrial cancer and kidneys - 200-600 mg / day.
At a temperature of 15-30 ° C.
Keep out of the reach of children.
Do not use after the expiry date printed on the package.